Terms: = Breast cancer AND PIK3R1, P27986, 5295, ENSG00000145675, p85-ALPHA, GRB1 AND Prognosis
10 results:
1. Bioinformatics identification and validation of aging‑related molecular subtype and prognostic signature in breast cancer.
Li J; Gao F; Su J; Pan T
Medicine (Baltimore); 2023 May; 102(19):e33605. PubMed ID: 37171324
[TBL] [Abstract] [Full Text] [Related]
2. 3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway.
Zhang L; Zheng Y; Zeng L; Zhang F; Che D; Cao Z; Huang C; Xian L; Zhang X; Zhang H; Guo Z
Life Sci; 2021 Nov; 285():119995. PubMed ID: 34592228
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Analysis of Metabolic Genes in breast cancer Based on Multi-Omics Data.
Hua Y; Gao L; Li X
Pathol Oncol Res; 2021; 27():1609789. PubMed ID: 34408553
[No Abstract] [Full Text] [Related]
4. An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer.
van der Noord VE; McLaughlin RP; Smid M; Foekens JA; Martens JWM; Zhang Y; van de Water B
Sci Rep; 2019 Sep; 9(1):13308. PubMed ID: 31527768
[TBL] [Abstract] [Full Text] [Related]
5. The prognostic effects of somatic mutations in ER-positive breast cancer.
Griffith OL; Spies NC; Anurag M; Griffith M; Luo J; Tu D; Yeo B; Kunisaki J; Miller CA; Krysiak K; Hundal J; Ainscough BJ; Skidmore ZL; Campbell K; Kumar R; Fronick C; Cook L; Snider JE; Davies S; Kavuri SM; Chang EC; Magrini V; Larson DE; Fulton RS; Liu S; Leung S; Voduc D; Bose R; Dowsett M; Wilson RK; Nielsen TO; Mardis ER; Ellis MJ
Nat Commun; 2018 Sep; 9(1):3476. PubMed ID: 30181556
[TBL] [Abstract] [Full Text] [Related]
6. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract] [Full Text] [Related]
7. Tumor Site and breast cancer prognosis.
Siotos C; McColl M; Psoter K; Gilmore RC; Sebai ME; Broderick KP; Jacobs LK; Irwin S; Rosson GD; Habibi M
Clin Breast Cancer; 2018 Oct; 18(5):e1045-e1052. PubMed ID: 29941391
[TBL] [Abstract] [Full Text] [Related]
8. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Pascual T; Apellániz-Ruiz M; Pernaut C; Cueto-Felgueroso C; Villalba P; Álvarez C; Manso L; Inglada-Pérez L; Robledo M; Rodríguez-Antona C; Ciruelos E
PLoS One; 2017; 12(7):e0180192. PubMed ID: 28727815
[TBL] [Abstract] [Full Text] [Related]
9. pik3r1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
Yan LX; Liu YH; Xiang JW; Wu QN; Xu LB; Luo XL; Zhu XL; Liu C; Xu FP; Luo DL; Mei P; Xu J; Zhang KP; Chen J
Int J Oncol; 2016 Feb; 48(2):471-84. PubMed ID: 26676464
[TBL] [Abstract] [Full Text] [Related]
10. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
Johannsdottir HK; Jonsson G; Johannesdottir G; Agnarsson BA; Eerola H; Arason A; Heikkila P; Egilsson V; Olsson H; Johannsson OT; Nevanlinna H; Borg A; Barkardottir RB
Int J Cancer; 2006 Sep; 119(5):1052-60. PubMed ID: 16570289
[TBL] [Abstract] [Full Text] [Related]
